Jazz Pharmaceuticals, through its JumpStart Program, offers patients support for its hematology/oncology drugs—Defitelio (defibrotide sodium), Erwinaze (asparaginase Erwinia chrysanthemi), and Vyxeos (daunorubicin and cytarabine) liposome (Table).
Defitelio is indicated for the treatment of patients with hepatic VOD (veno-occlusive disease) associated with renal or pulmonary dysfunction after hematopoietic stem-cell transplantation.
Erwinaze is indicated as a component of a multiagent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who are hypersensitive to Escherichia coli–derived asparaginase.
Vyxeos is indicated for adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) and for AML with myelodysplasia-related changes (AML-MRC).
The JumpStart Program
The JumpStart Program provides patients who are prescribed Defitelio, Erwinaze, or Vyxeos access to these medications through several financial assistance options. A patient assistance program is also offered for these 3 medications.
To be eligible for the JumpStart Program, a patient must:
- Be a legal US resident
- Have a valid prescription for Defitelio or for Erwinaze for indicated uses
- Receive treatment on an outpatient basis
- Have no insurance coverage or no coverage for Erwinaze, Defitelio, or Vyxeos.
In addition, the patient must provide proof of income, including ≥1 of these documents—a copy of a current federal income tax return, W-2 forms, yearly benefit statement (Social Security form 1099), pay stubs, and bank statements for 3 months for all earners in the household. For more information about eligibility and assistance, please contact JumpStart specialists at 888-837-4397 for Defitelio or Erwinaze, and at 855-589-9367 for Vyxeos.
Application & Enrollment
Completed JumpStart forms may be submitted by: